Cancer the invisible villain
Cancer has been a leading cause of death accounting to 18 million and since the 1971 US nation cancer act, continuing efforts are taken to decrease the death rate. This war against the deadly enemy is getting better by sharing knowledge, skills, and progress in this filed by international medical ties. Many governments even invite foreign nationals to conduct experiments to better the results also. In India breast cancer and stomach cancer is the leading cause of death in the area.
A brief history in research
The study takes almost 15 years before the lengthy process or regulation process comes in. Time and the right candidate are the biggest bottlenecks in the clinical trial phase. The international trials of “osimertinib” for lung cancer conducted in Asia, North America witnessed almost approval in 3 years and that is itself a record.
The project Orbis, a US FDA initiative review conducted with the Australian government in therapeutic goods administration showed good results, and parts of Asia and Europe are also been invited for such collaborations. Molecular alteration is very rare as of 1% type of cancer. The trails are transparent but the funding is not disclosed about firms (pharmaceutical) or government other giant companies. The data is subjected to frequent audits in the clinical stage and the intellectual property concerns are not vastly disturbed. Philanthropists and government regulators are putting pressure to help fight many deadly diseases all over the world mainly focussing on cancer. The US, China, and Europe have coordinated in many projects together. Switzerland and Japan have also mentioned their contributions very soon. Memorial Sloan Kettering center (MSK) in the United States is the oldest research center on the planet for more than 135 years showing its presence. Intellectual property protection is very much transparent when it comes to clinical trials.
The international collaboration often helps to combine various researchers and their knowledge.
